Both markedly and mildly elevated circulating homocysteine concentrations a
re associated with increased risk of vascular occlusion. Here we review pos
sible mechanisms that mediate these effects. Inborn errors of homocysteine
metabolism result in markedly elevated plasma homocysteine (200-300 mu mol/
L) and thromboembolic (mainly venous) disease: treatment to lower but not t
o normalize these concentrations prevents vascular events, Mild homocystein
e elevation (>15 mu mol/L) occurs in approximate to 20-30% of patients with
atherosclerotic disease. Usually, this is easily normalized with oral fola
te and ongoing trials are assessing the effect of folate treatment on outco
mes. Although there is evidence of endothelial dysfunction with both marked
ly and mildly elevated homocysteine concentrations, the elevated homocystei
ne concentration in atherosclerotic patients is also associated with most s
tandard vascular risk factors, and importantly, with early decline in renal
function, which is common in atherosclerosis. Decline in renal function al
one causes elevated plasma homocysteine land cysteine). These observations
suggest that mild hyperhomocysteinemia could often be an effect rather than
a cause of atherosclerotic disease. Data on the common C677T methylenetetr
ahydrofolate reductase polymorphism supports this, in that, although homozy
gosity is a frequent cause of mild hyperhomocysteinemia when plasma folate
is below median population concentrations, it appears not to increase cardi
ovascular risk. Indeed, there is recent evidence suggesting an acute antiox
idant effect of folic acid independent of its effect on homocysteine concen
trations. This antioxidant mechanism may oppose an oxidant effect of homocy
steine and be relevant to treatment of patients with vascular disease, espe
cially those with chronic renal insufficiency. Such patients have moderatel
y elevated plasma homocysteine and greatly increased cardiovascular risk th
at is largely unexplained.